Design Therapeutics reported a Q4 net loss of USD 16 million, with R&D expenses of USD 13.43 million. Q4 G&A expenses rose 5% to USD 4.74 million. For FY 2025, net loss widened 41% to USD 69.79 million, while R&D expenses increased 33% to USD 59.13 million. FY 2025 G&A expenses were USD 20.34 million, and cash, cash equivalents and investment securities were USD 219.85 million at year-end, which the company said is expected to fund planned operations into 2029. The company said trials for DT-216P2 (Friedreich ataxia) and DT-168 (FECD) are ongoing, and it expects to begin dosing DM1 patients with DT-818 in H1 2026, with DT-216P2 and DT-168 data anticipated in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9668306) on March 09, 2026, and is solely responsible for the information contained therein.